Dr. Al-Kali on FDA Approval of Inotuzumab Ozagamicin in ALL

Video

In Partnership With:

Aref Al-Kali, MD, hematologist, oncologist, Mayo Clinic, discusses the FDA approval of inotuzumab ozagamicin for the treatment of patients with acute lymphoblastic leukemia (ALL).

Aref Al-Kali, MD, hematologist, oncologist, Mayo Clinic, discusses the FDA approval of inotuzumab ozagamicin for the treatment of patients with acute lymphoblastic leukemia (ALL).

Related Videos
Sarah E. S. Leary, MD, MS, attending physician, medical director, Pediatric Brain Tumor Program, Seattle Children’s Hospital; professor, Department of Pediatrics, University of Washington School of Medicine
Marc J. Braunstein, MD, PhD
Rita Nanda, MD
Vikram Narayan, MD
Daniel Olson, MD
Vishal Patel, MD, FAAD, FACMS, associate professor, Dermatology, George Washington (GW) School of Medicine & Health Sciences
Catherine C. Coombs, MD, associate clinical professor, medicine, University of California, Irvine School of Medicine
Jorge J. Castillo, MD,
Heinz-Josef Lenz, MD, FACP
Sundar Jagannath, MBBS, director, Center of Excellence for Multiple Myeloma, professor of medicine (hematology and medical oncology), The Tisch Cancer Institute, Mount Sinai
Related Content
US FDA

FDA Grants Breakthrough Therapy Designation to Ziftomenib in NPM1-Mutant AML

April 22nd 2024
Article
OncLive On Air

Revisit the OncLive On Air Episodes From February 2024

March 18th 2024
Podcast
OncLive On Air

Revisit Every OncLive On Air Episode from March 2024

April 19th 2024
Article
Matthew Lunning, DO, FACP

Lunning and Jacobson Dissect the Role of CAR T-Cell Therapy in Follicular Lymphoma

November 30th 2023
Podcast
David L. Porter, MD

Call for Boxed Warning for Secondary Malignancies on CAR T-Cell Therapies Raises Alarm, But Key Questions Remain

April 18th 2024
Article
Walter Klemp of Moleculin

EMA Grants Orphan Drug Designation to Annamycin in AML

April 18th 2024
Article